Surveillance of pneumococcal resistance in Belgium during winter 1996- 1997

Acta Clinica Belgica

Volumn 53, Issue 4, 1998, Pages 275-281

  Vanhoof, R ^a   Carpentier, M ^b   Glupczynski, Y ^c   Gordts, B ^d   Magerman, K ^e   Mans, Y ^a   Nyssen, H J ^a   Simon, A C ^f   Surmont, I ^g   Van De Vyvere, M ^h   Van Landuyt, H ^d   Van Nimmen, L ⁱ   Van Noyen, R ^j  

^a PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

^b Centre Hospitalier Regional de La Citadelle   (Belgium)

^c Laboratoire de Microbiologie   (Belgium)

^d General Hospital St Jan   (Belgium)

^e VIRGA JESSE HOSPITAL   (Belgium)

^f Laboratoire de Microbiologie   (Belgium)

^g Heilig Hart Ziekenhuis   (Belgium)

^h Stuivenberg General Hospital   (Belgium)

ⁱ Algemeen Ziekenhuis Jan Palfijn   (Belgium)

^j IMELDA HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFOTAXIME; CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN; IMIPENEM; PENICILLIN G; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BELGIUM; DRUG POTENCY; HEALTH SURVEY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS PNEUMONIAE; WINTER;

EID: 7844239319     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.1998.11754175     Document Type: Article

References (29)

1. Hansman D, Bullen MM. A resistant pneumococcus. Lancet. 1967; ii: 264-5.
2. Baquero F. Pneumococcal resistance to β-lactam antibiotics: a global geographic overview. Microbial Drug Resistance. 1995; 1: 115-20.
3. Klugman K, Goldstein F. Kohno S, Baquero F. The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Inf. 1997; 3 (Suppl. 1): S48-60.
4. Tarasi A, Chong Y. Lee K. Tomasz A. Spread of serotype 23F multidrug-resistant Streptococcus pneumoniae clone to South Korea. Microbial Drug Resistance. 1997; 3: 105-9.
5. Pradier C, Dunais B. Carsenti-Etesse H, Dellamonica P. Pneumococcal resistance patterns in Europe. Eur J Clin Microbiol Infect Dis. 1997; 16: 644-7.
6. Hermans PWM. Sluijter M, Elzenaar K, et al. Penicillin-resistant Streptococcuspneumoniae in the Netherlands: results of a 1-year molecular epidemiology survey. J Infect Dis. 1997; 175: 1413-22.
7. Ferroni A, Nguyen N, Gehanno P, Boucot I, Berche P. Clonal distribution of penicillin-resistant Streptococcus pneumoniae 23F in France. J Clin Microbiol. 1996. 34: 2707-12.
8. Vanhoof R, Carpentier M, Glupczynski Y, et al. In vitro susceptibilities of 176 clinical isolates of Streptococcus pneumoniae to 11 beta-lactams, erythromycin, and tetracycline. Acta Clin Belg. 1996; 51: 377-85.
9. Ruoff KL. Streptococcus. In. Murray PR. Ed. Manual of Clinical Microbiology. Sixth Edition. Washington. D.C.: ASM. 1995: 299-307.
10. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. NCCLS Document M7-A4, Vol. 17 No. 2, Villanova PA, 1997).
11. Sutcliffe J, Tait-Kamradt A. Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 1996. 40: 1817-24.
12. Tait-Kamradt A. Clancy J. Cronan M, et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997; 41: 2251-5.
13. Pankuch GA, Jacobs MR, Appelbaum PC. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother. 38: 2065-72 (1994).
14. Jorgensen JH, Swenson JM, Tenover FC, et al. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae. J Clin Microbiol. 1996; 34: 2679-84.
15. Frémaux A, Sissia G, Rosenbaum M, Geslin P. In vitro activity of cefpirome (HR 810), a new parenteral cephalosporin, against penicillin susceptible and resistant pneumococci. In: Program and Abstracts of the Thirty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. Abstract 1020, p. 280. ASM, Washington, D.C.
16. Spangler SK, Jacobs MR, Appelbaum PC. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxycillin, amoxycillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother. 1994; 38: 2902-4.
17. Pankuch GA. Jacobs MR. Appelbaum PC. Comparative activity of ampicillin, amoxycillin. amoxycillin/ clavulanate and cefotaxime against 189 penicillin susceptible and -resistant pneumococci. J Antimicrob Chemother. 1995; 35: 883-8.
18. Jacobs MR. Respiratory tract infection: epidemiology and surveillance. J Chemother. 1997; 9 (Suppl. 3): 10-7.
19. Goldstein FW, Garau J. 30 years of penicillin-resistant S. pneumoniae: myth or reality ? Lancet. 1997: ii: 233-4.
20. Spangler SK, Jacobs MR, Appelbaum PC. Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other β-lactams. J Antimicrob Chemother. 1997; 39: 141-8.
21. Appelbaum PC. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae. Ped Infect Dis J. 1996; 15: 932-9.
22. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. NCCLS Document M 100-S6, Vol. 15 No. 14, Villanova PA, 1995.
23. Mortensen JE. Streptococcus pneumoniae, otitis media and antimicrobial breakpoints. Ped Infect Dis J. 1997; 16: 537.
24. Goldstein FW. Choice of an oral β-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae. Scand J Infect Dis. 1997; 29: 255-7.
25. Jacobs MR. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Ped Infect Dis J. 1996; 15: 940-3.
26. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26: 1-12.
27. Dagan R. Can the choice of antibiotics for therapy of acute otitis media be logical ? Eur J Clin Microbiol Infect Dis. 1998; 17: 1-5.
28. Dagan R, Melamed R, Zamir O, Leroy O. Safety, and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Ped Infect Dis J. 1997; 16: 1053-9.
29. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Ped Infect Dis J. 1997; 16: 1060- 4.